Comirnaty® and Spikevax® (KP.2) 2024 – 2025 vaccines – FDA approval and Emergency Use Authorization
August 22, 2024 - FDA approved Pfizer/BioNTech’s Comirnaty (KP.2) and Moderna’s Spikevax (KP.2) COVID-19 vaccine in individuals 12 years of age and older as a single dose at least 2 months since the last dose of any COVID-19 vaccine.